Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Robert Flisiak & Marta Flisiak-Jackiewicz. (2017) Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Review of Gastroenterology & Hepatology 11:6, pages 559-567.
Read now
Read now
Articles from other publishers (12)
Mohamed El Kassas, Mohamed Alboraie, Heba Omar, Yasmeen Abd El Latif, Mohammed Abd Algaber, Adel El Tahan, Hesham El Halwagy, Shimaa Afify, Magdy Elserafy, Kadry Elsaeed & Wahid Doss. (2019) High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results. Journal of Medical Virology 94:2, pages 667-674.
Crossref
Crossref
Iosif Marincu, Felix Bratosin, Manuela Curescu, Oana Suciu, Mirela Turaiche, Bianca Cerbu & Iulia Vidican. (2021) Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania. Medicina 57:9, pages 986.
Crossref
Crossref
Jingjing Wu, Peng Huang, Haozhi Fan, Ting Tian, Xueshan Xia, Zuqiang Fu, Yan Wang, Xiangyu Ye, Ming Yue & Yun Zhang. (2019) Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis. Virology Journal 16:1.
Crossref
Crossref
Pek Y. Chong, J. Brad Shotwell, John Miller, Daniel J. Price, Andy Maynard, Christian Voitenleitner, Amanda Mathis, Shawn Williams, Jeffrey J. Pouliot, Katrina Creech, Feng Wang, Jing Fang, Huichang Zhang, Vincent W.-F. Tai, Elizabeth Turner, Kirsten M. Kahler, Renae Crosby & Andrew J. Peat. (2019)
Design of
N
-Benzoxaborole Benzofuran GSK8175—Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor
. Journal of Medicinal Chemistry 62:7, pages 3254-3267.
Crossref
Crossref
Antonija Verhaz, Zdravka Kezić, Miloš StojiljkovićP.P. & Ranko Škrbić. (2019) Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study. Scripta Medica 50:2, pages 77-81.
Crossref
Crossref
R. Flisiak, E. Janczewska, M. Łucejko, E. Karpińska, D. Zarębska-Michaluk, K. Nazzal, B. Bolewska, J. Białkowska, H. Berak, K. Fleischer-Stępniewska, K. Tomasiewicz, K. Karwowska, K. Simon, A. Piekarska, O. Tronina, E. Tuchendler & A. Garlicki. (2018) Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. Journal of Viral Hepatitis 25:11, pages 1298-1305.
Crossref
Crossref
David A. DeGoey, Hui-Ju Chen, Philip B. Cox & Michael D. Wendt. (2017) Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection. Journal of Medicinal Chemistry 61:7, pages 2636-2651.
Crossref
Crossref
Carmen M. Preda, Corneliu P. Popescu, Cristian Baicus, Theodor A. Voiosu, Mircea Manuc, Corina Silvia Pop, Liana Gheorghe, Ioan Sporea, Anca Trifan, Marcel Tantau, Alina Tantau, Emanoil Ceausu, Doina Proca, Ileana Constantinescu, Simona M. Ruta, Mircea M. Diculescu & Alexandru Oproiu. (2018) Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver International 38:4, pages 602-610.
Crossref
Crossref
John T. Randolph, A. Chris Krueger, Pamela L. Donner, John K. Pratt, Dachun Liu, Christopher E. Motter, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Hock B. Lim, Jill M. Beyer, Rubina Mondal, Neeta S. Panchal, Lynn Colletti, Yaya Liu, Gennadiy Koev, Warren M. Kati, Lisa E. Hernandez, David W. A. Beno, Kenton L. Longenecker, Kent D. Stewart, Emily O. Dumas, Akhteruzzaman Molla & Clarence J. Maring. (2018)
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a
trans
-Stilbene Analog with Good Oral Bioavailability
. Journal of Medicinal Chemistry 61:3, pages 1153-1163.
Crossref
Crossref
Mariusz Łucejko & Robert Flisiak. (2018) Quantitative Measurement of HCV Core Antigen for Management of Interferon-Free Therapy in HCV-Infected Patients. Antiviral Therapy 23:2, pages 149-156.
Crossref
Crossref
Erica Godinho Menezes, Jordana Grazziela Alves Coelho-dos-Reis, Ludmila Melo Cardoso, Ágata Lopes-Ribeiro, Juan Jonathan-Gonçalves, Marco Túlio Porto Gonçalves, Rodrigo Dias Cambraia, Eric Bassetti Soares, Luciana Diniz Silva, Vanessa Peruhype-Magalhães, Maria Rios, Caren Chancey, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho & Rosângela Teixeira. (2017) Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases. Antiviral Research 141, pages 19-28.
Crossref
Crossref
R. Flisiak, E. Janczewska, M. Wawrzynowicz‐Syczewska, J. Jaroszewicz, D. Zarębska‐Michaluk, K. Nazzal, B. Bolewska, J. Bialkowska, H. Berak, K. Fleischer‐Stępniewska, K. Tomasiewicz, K. Karwowska, K. Rostkowska, A. Piekarska, O. Tronina, G. Madej, A. Garlicki, M. Lucejko, A. Pisula, E. Karpińska, W. Kryczka, A. Wiercińska‐Drapało, I. Mozer‐Lisewska, M. Jabłkowski, A. Horban, B. Knysz, M. Tudrujek, W. Halota & K. Simon. (2016) Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Alimentary Pharmacology & Therapeutics 44:9, pages 946-956.
Crossref
Crossref